<DOC>
	<DOCNO>NCT00441870</DOCNO>
	<brief_summary>This Phase 1 clinical trial evaluate safety tolerability escalate dos EC0225 patient refractory metastatic tumor exhaust standard therapeutic option .</brief_summary>
	<brief_title>Study EC0225 Treatment Refractory Metastatic Tumors</brief_title>
	<detailed_description>This Phase 1 , dose escalation study EC0225 administer intravenous bolus ( IV ) week 1 3 4-week cycle patient refractory metastatic cancer exhaust standard therapeutic option . EC0225 drug specifically design enter cell via folate vitamin receptor . Experimental evidence show target receptor over-expressed many human cancer . There previous human study EC0225 ; however , lab research ( research test tube animal ) use EC0225 show activity tumor animal . This activity animal model suggest EC0225 may useful chemotherapy human cancer . The primary objective study determine safety maximum tolerate dose EC0225 give intravenous bolus . The efficacy treatment also measure .</detailed_description>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>18 year age old Histological cytological diagnosis neoplasm No effective standard therapeutic option ECOG performance status 02 ≥ 4 week post therapeutic radiation chemotherapy ( ≥ 6 week nitrosureas ) recovery ( baseline status ) associate acute toxicity . Patients previously treat noncytotoxic therapy recover control drugassociated toxicity allow enter trial period consist 4 halflives agent . Negative serum pregnancy test woman childbearing potential within one week prior treatment investigational agent ( 99mTcEC20 EC0225 ) Adequate bone marrow reserve , renal hepatic function Concurrent malignancy Women pregnant lactate Evidence symptomatic brain metastasis Receiving concomitant anticancer therapy ( exclude supportive care ) Requires palliative radiotherapy time study entry Unable tolerate condition radionuclide image Administration another radiopharmaceutical would interfere assessment 99mTcEC20</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Phase 1</keyword>
	<keyword>EC0225</keyword>
	<keyword>EC20</keyword>
	<keyword>Refractory</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Experimental</keyword>
</DOC>